Chemotherapy for myeloid malignancy in children with Fanconi anemia
- 11 April 2006
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 48 (7), 668-672
- https://doi.org/10.1002/pbc.20843
Abstract
Background Children with Fanconi anemia (FA) have a markedly increased risk of developing myeloid malignancies. Historically, patients with FA and myeloid malignancy have extremely poor outcomes. There are currently no clinical trials or case series addressing the use of chemotherapy for children with FA, except in the context of preparative regimens for stem cell transplantation (SCT). In this report we describe the toxicity of a chemotherapy approach for patients with FA and myeloid malignancy to achieve cytoreduction prior to SCT. Patients and Methods Four patients with FA and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) were treated with chemotherapy (fludarabine 30 mg/m2 and cytosine arabinoside 300 mg/m2 each on days 2–4 and granulocyte‐colony stimulating factor (G‐CSF) 5 µg/kg on days 1–5), termed reduced intensity FLAG prior to SCT. Results The chemotherapy was well tolerated with expected hematologic toxicity and no measurable toxicity in other organs. Two of the three patients with AML cleared blasts from their bone marrow. Reduction in marrow cellularity was also achieved in one patient with hypercellular MDS. Conclusion These data indicate that children with FA and myeloid malignancy can tolerate chemotherapy and achieve clearance of disease. It remains unclear whether pre‐SCT chemotherapy improves currently poor survival rates for SCT in FA patients with myeloid malignancies and further studies are needed to determine if there is a clinical role for this strategy. Pediatr Blood Cancer 2007;48:668–672.Keywords
This publication has 21 references indexed in Scilit:
- A Rapid Method for Retrovirus-Mediated Identification of Complementation Groups in Fanconi Anemia PatientsMolecular Therapy, 2005
- Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemiaBlood, 2004
- Microcephalus, medulloblastoma and excessive toxicity from chemotherapy: an unusual presentation of Fanconi anaemiaActa Paediatrica, 2001
- Diabetes insipidus revealing acute myelogenous leukaemia with a high platelet count, monosomy 7 and abnormalities of chromosome 3: a new entity?European Journal of Haematology, 2001
- Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell graftsBritish Journal of Haematology, 2000
- Lymphoblastic Lymphoma and Excessive Toxicity From ChemotherapyJournal of Pediatric Hematology/Oncology, 1999
- IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trialBritish Journal of Haematology, 1998
- Unrelated donor bone marrow transplantation in Fanconi anaemia: the Leiden experienceBone Marrow Transplantation, 1998
- Acute Myeloid Leukemia and Diabetes insipidus: Results in 5 PatientsActa Haematologica, 1995
- Acute myelogenous leukemia (AML) and diabetes insipidus (DI): Further association with monosomy 7Hematological Oncology, 1992